The evolving science of Parkinson’s: briefing on disease-modifying research

In April 2026, Dr Laurie Sanders, a leading neuroscientist from Duke University, presented a comprehensive update on the biological drivers of Parkinson's. The core message of the briefing was a shift in perspective: Parkinson’s is no longer viewed simply as a movement disorder caused by dopamine loss, but as a multisystem, whole-body journey. Historically, the field focused almost exclusively on the motor symptoms described by James Parkinson in 1817 and the subsequent development of levodopa in 1961. Today, research has moved into the "molecular era," where scientists are targeting the underlying cellular pathways to develop disease-modifying therapies—treatments designed to slow or stop the condition's progression rather than just masking symptoms. The three interconnected drivers of Parkinson's Dr Sanders identified three primary biological pathways that drive the progression of Parkinson's. Crucially, these are no longer viewed in isolation; they form an interconnected web where one dysfunction frequently triggers another. 1. Alpha-synuclein: The complex protein target Alpha-synuclein is a protein naturally found in all brain cells, playing a vital role in communication between neurons and the release of neurotransmitters like dopamine. Pathology: In Parkinson's, this protein misfolds and clumps into higher-order structures called oligomers and fibrils, eventually forming Lewy bodies. Propagation: Modern evidence suggests these misfolded proteins can spread between cells in a "prion-like" manner, moving across different brain regions and even between the gut and the brain. Therapeutic challenge: Because the protein has a normal, healthy function, researchers must find ways to selectively clear only the toxic, misfolded forms without disrupting the protein's essential roles. 2. Mitochondrial dysfunction: More than energy production Mitochondria are often called the "powerhouses" of the cell, but they also manage DNA repair, cell death signalling, and metabolism. Complex I defect: A specific defect in "Complex I"—the gatekeeper of mitochondrial energy production—is a hallmark of Parkinson's, observed in the brain, muscle, and blood. Vulnerability: Dopamine neurons are uniquely susceptible to this dysfunction because they have incredibly long axons, requiring a massive and constant energy supply to function over such great distances. Environmental links: Certain toxins, such as paraquat and rotenone, are known to disrupt this exact mitochondrial pathway, mimicking the features of Parkinson's in research models. 3. Neuroinflammation: A chronic cycle The brain’s immune cells, such as microglia, normally act as a "cleanup crew" to protect the brain. Chronic activation: In Parkinson's, these cells can become permanently "switched on," releasing inflammatory substances that further damage healthy neurons. The Leaky Barrier: A compromised blood-brain barrier may allow peripheral immune cells into the brain, adding to the inflammatory burden. The Gut-Brain Axis: Inflammation may also travel from the gut to the brain via the vagus nerve, suggesting that the condition's origins may be peripheral for some people. Precision medicine and the role of biomarkers The most significant hurdle in Parkinson's research is heterogeneity—the fact that the condition looks and progresses differently in every person. To solve this, Dr Sanders emphasized the shift toward precision medicine, matching the right treatment to the right person based on their specific biology. The MtDNA-DX breakthrough Dr Sanders’ lab at Duke has developed a PCR-based blood test called MtDNA-DX. Function: It measures damage to mitochondrial DNA as a biomarker for early-stage Parkinson's. Speed: The test can go from a simple blood sample to a result in just one day. Purpose: This allows researchers to identify individuals whose Parkinson's is primarily driven by mitochondrial failure, ensuring they are enrolled in clinical trials for drugs specifically designed to fix that pathway. Looking ahead: Combination therapies Dr Sanders concluded that the failure of many past clinical trials may be due to targeting only one pathway at a time. Because alpha-synuclein, mitochondria, and inflammation are so deeply intertwined, the next generation of research is moving toward combination therapies. By using biomarkers to identify a person's specific "biological signature," doctors may soon be able to prescribe a cocktail of treatments that address multiple pathways simultaneously—halting the toxic spread of proteins, boosting cellular energy, and calming chronic inflammation all at once.